Complications of palliative antiangiogenic therapy in patients with colorectal cancer
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Introduction: Bevacizumab is an antiangiogenic drug used in the therapy of numerous solid tumours including colorectal adenocarcinoma. The efficacy and safety of bevacizumab has been demonstrated in many multicenter clinical trials. The scope of this paper is to analyze the safety profile of bevacizumab in patients with stage IV colorectal cancer.
Authors and Affiliations
Małgorzata Domagała-Haduch, Marek Jasiówka, Łukasz Nowak, Ida Cedrych
Keywords
Related Articles
- EP ID EP186912
- DOI 10.5604/01.3001.0009.5069
- Views 204
- Downloads 0
Imaging for Cardiotoxicity: Many Issues, Many Questions
Health and disease – medical and psychological aspects of quality of life in patients with gynecological cancers
Gynecological cancers, due to their location and relation to the aspects of femininity, reproductive ability and body image, are associated not only with the physical dimension of cancer, but also with the mental sphere....
New possibilities of therapy for advanced, metastatic breast cancer
Despite improving screening methods, diagnosis of early breast cancers, new therapies the prognosis in breast cancer remains poor. Advanced, metastatic breast cancer is an incurable, persistent disease. Hormonotherapy is...
Tumor lysis syndrome
Tumor lysis syndrome is a life-threatening oncological emergency occurring in response to chemotherapy or spontaneously as a result of massive and rapid breakdown of malignant cells. The release of their contents into ci...
Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma
Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient...